Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP825020.RATk_sP_AAaHe3KZ8Q18yIV5PbnGZb34IvG4qMpiQqPLU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP825020.RATk_sP_AAaHe3KZ8Q18yIV5PbnGZb34IvG4qMpiQqPLU130_assertion type Assertion NP825020.RATk_sP_AAaHe3KZ8Q18yIV5PbnGZb34IvG4qMpiQqPLU130_head.
- NP825020.RATk_sP_AAaHe3KZ8Q18yIV5PbnGZb34IvG4qMpiQqPLU130_assertion description "[Eight weeks after disease induction, anti-PDGF-D therapy significantly ameliorated focal segmental glomerulosclerosis, podocyte damage (de novo desmin expression), tubulointerstitial damage, and fibrosis as well as the accumulation of renal interstitial matrix including type III collagen and fibronectin.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP825020.RATk_sP_AAaHe3KZ8Q18yIV5PbnGZb34IvG4qMpiQqPLU130_provenance.
- NP825020.RATk_sP_AAaHe3KZ8Q18yIV5PbnGZb34IvG4qMpiQqPLU130_assertion evidence source_evidence_literature NP825020.RATk_sP_AAaHe3KZ8Q18yIV5PbnGZb34IvG4qMpiQqPLU130_provenance.
- NP825020.RATk_sP_AAaHe3KZ8Q18yIV5PbnGZb34IvG4qMpiQqPLU130_assertion SIO_000772 16510766 NP825020.RATk_sP_AAaHe3KZ8Q18yIV5PbnGZb34IvG4qMpiQqPLU130_provenance.
- NP825020.RATk_sP_AAaHe3KZ8Q18yIV5PbnGZb34IvG4qMpiQqPLU130_assertion wasDerivedFrom befree-20140225 NP825020.RATk_sP_AAaHe3KZ8Q18yIV5PbnGZb34IvG4qMpiQqPLU130_provenance.
- NP825020.RATk_sP_AAaHe3KZ8Q18yIV5PbnGZb34IvG4qMpiQqPLU130_assertion wasGeneratedBy ECO_0000203 NP825020.RATk_sP_AAaHe3KZ8Q18yIV5PbnGZb34IvG4qMpiQqPLU130_provenance.